about
Colloquium paper: uniquely human evolution of sialic acid genetics and biologyTGN1412: From Discovery to DisasterCase report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cellsDarwin and Fisher meet at biotech: on the potential of computational molecular evolution in industry.After TGN1412: recent developments in cytokine release assays.Dynamics of a cytokine storm.Immunotoxicity assessment of rice-derived recombinant human serum albumin using human peripheral blood mononuclear cells.Safety Profile of Amnion-Derived Cellular Cytokine Solution (ACCS) Following Topical Skin Application in Patients Receiving Breast Radiotherapy.Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges.Harnessing nanoparticles for immune modulationFibroblast growth factor receptor 3 (FGFR3) associated with the CD20 antigen regulates the rituximab-induced proliferation inhibition in B-cell lymphoma cellsDetermination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes.OX40:OX40L axis: emerging targets for improving poxvirus-based CD8(+) T-cell vaccines against respiratory virusesThe yin and yang of immunomodulatory biologics: assessing the delicate balance between benefit and risk.A historical perspective of immunotoxicology.Pharmacology-based toxicity assessment: towards quantitative risk prediction in humans.[From the licensure of vaccines to the recommendation of the Standing Committee on Vaccination in Germany : criteria for the assessment of benefits and risks].Model-Based Discovery and Development of Biopharmaceuticals: A Case Study of Mavrilimumab.
P2860
Q24634579-E1E43E1E-E78F-4101-A0DA-4DA85569FCEFQ28972456-285DD665-E62C-4584-B056-E1215323E5DBQ29620608-926D4986-5C85-499D-ACB6-C258F61E479BQ30048609-6B1E16EE-BD25-423D-8EF7-9D886B3B0FF7Q30388839-87F6D7D7-95C4-40E2-BDB3-6F6F4BD91875Q34299057-3C6EEE79-7FB3-4C2C-BB1E-FAC047F5A297Q34437535-623695AA-EA6A-4020-B821-BFC27A6E367FQ35220369-89EFB022-833D-48F8-84A6-90B0C93E28A5Q35908320-148386CF-8267-4D60-ACFC-8346C66D7BBFQ35929084-6F39B42B-3DA3-43A6-95EC-E6975D3ECF4AQ36154772-734B479A-17B3-46C2-927A-CD9431C0E4F6Q36347760-0198D8D8-5246-4627-8EFA-C080861F6C6BQ37496388-882169F2-5B1C-403C-968A-B625CCCD3B69Q37883029-F87291FA-C1F4-466A-9BFE-083317F1AE31Q37948126-C5F55C05-4D81-4CE3-AB5A-56899D140874Q37973651-1F94D01D-FE08-499F-935A-8E5E576743ECQ38148271-CA261881-48C0-4DD4-BACA-143D40E809F7Q38771635-B17D46CC-F122-4A9F-9DD6-5CBF3F53B260Q41558226-559F40F3-EC9F-48EB-9144-F76AC402A15BQ49447486-16A4FE17-51F9-4EF6-84F6-8D441917C4F4
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Safety of biologics, lessons learnt from TGN1412
@ast
Safety of biologics, lessons learnt from TGN1412
@en
Safety of biologics, lessons learnt from TGN1412
@nl
type
label
Safety of biologics, lessons learnt from TGN1412
@ast
Safety of biologics, lessons learnt from TGN1412
@en
Safety of biologics, lessons learnt from TGN1412
@nl
prefLabel
Safety of biologics, lessons learnt from TGN1412
@ast
Safety of biologics, lessons learnt from TGN1412
@en
Safety of biologics, lessons learnt from TGN1412
@nl
P2093
P1476
Safety of biologics, lessons learnt from TGN1412
@en
P2093
Richard Stebbings
Robin Thorpe
Stephen Poole
P356
10.1016/J.COPBIO.2009.10.002
P407
P577
2009-12-01T00:00:00Z